Day 126: 26th July 2020

The coronavirus is still surging… yet hopes for a solution are high!

The big news!

Indian-built device SHYCOCAN to contain Covid infectivity gets US, EU nod

This innovative technology is intended to ‘physically attenuate’ the homing mechanism on the virus and prevent infectivity

– Dr. Rajah Vijay Kumar – SHYCOCAN device inventor, Chairman and Chief Scientific Officer of the Organization de Scalene and Scalene Cybernetics Ltd., and long-standing technology partner of the Shreis Scalene Group of US Companies.

The device is designed to release a very high concentration of environmentally safe electrons to emit and excite photons with the required kinetic energy. As the photons bombard bulk surfaces and suspended particles in confined environments, the emanated electron cloud actively ‘disarms’ air and surface transmission of the Corona family of viruses.

SHYCOCAN: Image from The Times Of India

The SHYCOCAN does not use any chemicals nor does it produce ozone, or ionize the air to produce reactive oxygen species, oxides of nitrogen or other harmful compounds.

The device can be safely deployed in all environments inhabited by people, be it very large or small enclosed spaces.

An important feature of this technology is that only the Corona family of viruses is targeted, while bacteria, fungi or other eco-friendly micro-organisms are not, allowing for 24/7, safe deployment.

Shreis Scalene Therapeutics LLC (SSTx), a MD-USA-based medical device company will fast-track the manufacture and distribution of the CE-marked (EU-Class 1) Scalene Hypercharge Corona Canon (SHYCOCAN) under US FDA ‘Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.”

Read more about other innovative projects to fight coronavirus here.

Oxford vaccine triggers immune response

The much awaited result of the Oxford vaccine trial is positive. Trials involving 1,077 people showed the injection led to them making antibodies and T-cells that can fight coronavirus. The findings are hugely promising, but it is still too soon to know if this is enough to offer protection and larger trials are under way.

There were no dangerous side-effects from taking the vaccine, however, 70% of people on the trial developed either fever or headache. The researchers say this could be managed with paracetamol.

More than 10,000 people will take part in the next stage of the trials in the UK.

However, the trial has also been expanded to other countries because levels of coronavirus are low in the UK, making it hard to know if the vaccine is effective. There will be a large trial involving 30,000 people in the US as well 2,000 in South Africa and 5,000 in Brazil.

Serum Institute of India has sought permission from the drug regulator to conduct human clinical trials for a covid vaccine being developed by Oxford University of the U.K. and Swedish drugmaker AstraZeneca Plc.

Serum Institute of India has entered a manufacturing partnership with AstraZeneca to produce and supply one billion doses of the Covid-19 vaccine being developed by Oxford University. These vaccines will be for India and middle and low income countries across the world, he had said.

Coronavirus vaccine — COVAXIN — shows encouraging results

First part of phase-1 of vaccine trial (Covaxin) has been completed. 50 people across India were administered the vaccine and the results were encouraging.

Covaxin is India’s first coronavirus vaccine developed in collaboration between Bharat Biotech and ICMR.

Recovered Delhi cop tests positive again, raises question if coronavirus can reinfect

The case of a Delhi policeman having a relapse of the novel coronavirus has baffled experts and the doctors.

The policeman, 50, had tested positive for the virus in May and was treated at the Indraprastha Apollo hospitals between May 15 and 22. Thereafter, he had tested negative and resumed duty.

However, on July 10, he again felt unwell with a fever and dry cough and got himself tested on July 13. The report came positive through the rapid antigen test as well as the RT-PCR test.

The first time he was tested for coronavirus, he had no symptoms. There was a camp in the hospital and since his friend got tested, he also got tested and came positive. The second time the policeman was tested for antibodies too, but it was found that he did not have antibodies.

The reason: It could have been a false positive first test or that a right level of antibodies was not developed against the virus which meant that when the patient was exposed again, he got reinfected.

The verdict: Don’t lower your guard even if you have been infected once. The reinfection mystery is yet to be solved.

Coronavirus Cases:


Cases in India: 1,389,221

July 26, 2020, 09:44 GMT

How do people catch coronavirus? What we know so far

We have come a long way since the first infections. Even though a cure hasn’t been found, we now understand the virus a lot better and can take effective prevention and treatment measures.

Read here for an explanation of the established route of how covid-19 spreads and other pathways under investigation.

And remember, we should be treating the vaccine as just another approach to fight the pandemic, not the best approach. A lot more measures and non-pharmaceutical interventions are the key to restraining the spread of the virus.

Take care and stay safe!

One thought on “Day 126: 26th July 2020

Share your thoughts...

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s